Cargando…

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is caused by absence of the integral structural protein, dystrophin, which renders muscle fibres susceptible to injury and degeneration. This ultimately results in cardiorespiratory dysfunction, which is the predominant cause of death in DMD patients, and highlights...

Descripción completa

Detalles Bibliográficos
Autores principales:	Betts, Corinne A., Saleh, Amer F., Carr, Carolyn A., Muses, Sofia, Wells, Kim E., Hammond, Suzan M., Godfrey, Caroline, McClorey, Graham, Woffindale, Caroline, Clarke, Kieran, Wells, Dominic J., Gait, Michael J., Wood, Matthew J. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586900/ https://www.ncbi.nlm.nih.gov/pubmed/26113184 http://dx.doi.org/10.1038/srep11632

Ejemplares similares

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
por: Betts, Corinne A., et al.
Publicado: (2015)

Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy
por: Shabanpoor, Fazel, et al.
Publicado: (2015)

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
por: Gait, Michael J., et al.
Publicado: (2019)

Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics
por: Coenen-Stass, Anna M. L., et al.
Publicado: (2015)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
por: Betts, Corinne A, et al.
Publicado: (2019)

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
por: Blain, Alison M., et al.
Publicado: (2018)

Corrigendum: Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics
por: Coenen-Stass, Anna M. L., et al.
Publicado: (2016)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012)

Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides
por: Tone, Yuichiro, et al.
Publicado: (2021)

Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy
por: Alves, Francesca M., et al.
Publicado: (2022)

A New Extensively Characterised Conditionally Immortal Muscle Cell-Line for Investigating Therapeutic Strategies in Muscular Dystrophies
por: Muses, Sofia, et al.
Publicado: (2011)

Tracking progress: an update on animal models for Duchenne muscular dystrophy
por: Wells, Dominic J.
Publicado: (2018)

Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy
por: Roberts, Thomas C, et al.
Publicado: (2012)

Muscle Pathology in Dystrophic Rats and Zebrafish Is Unresponsive to Taurine Treatment, Compared to the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Terrill, Jessica R., et al.
Publicado: (2023)

Macroglossia and less advanced dystrophic change in the tongue muscle of the Duchenne muscular dystrophy rat
por: Yamanouchi, Keitaro, et al.
Publicado: (2022)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
por: Betts, Corinne, et al.
Publicado: (2012)

Proteome Profiling of the Dystrophic mdx Mice Diaphragm
por: Mucha, Olga, et al.
Publicado: (2023)

Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy
por: Hildyard, John CW, et al.
Publicado: (2016)

Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
por: Järver, Peter, et al.
Publicado: (2015)

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
por: van Westering, Tirsa L.E., et al.
Publicado: (2019)

Dystrophic muscles get overexcited
por: Wells, William A.
Publicado: (2004)

Initial Pulmonary Respiration Causes Massive Diaphragm Damage and Hyper-CKemia in Duchenne Muscular Dystrophy Dog
por: Nakamura, Akinori, et al.
Publicado: (2013)

Ultrasonography validation for early alteration of diaphragm echodensity and function in the mdx mouse model of Duchenne muscular dystrophy
por: Mele, Antonietta, et al.
Publicado: (2021)

Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
por: van Westering, Tirsa L. E., et al.
Publicado: (2015)

Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in the dystrophic muscle in Duchenne muscular dystrophy
por: Vu Hong, Ai, et al.
Publicado: (2022)

Dystrophic phenotype improvement in the diaphragm muscle of mdx mice by diacerhein
por: Mâncio, Rafael Dias, et al.
Publicado: (2017)

Spatial and age-related changes in the microstructure of dystrophic and healthy diaphragms
por: Henry, Catherine C., et al.
Publicado: (2017)

Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration
por: Roberts, Thomas C., et al.
Publicado: (2015)

Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice
por: Miura, Yasutomo, et al.
Publicado: (2022)

Dystrophic Myopathy of the Diaphragm with Recurrent Severe Respiratory Failure is Congenital Myasthenic Syndrome 11
por: Kramer, J.J., et al.
Publicado: (2023)

NADPH oxidase mediates microtubule alterations and diaphragm dysfunction in dystrophic mice
por: Loehr, James Anthony, et al.
Publicado: (2018)

Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics
por: McClorey, Graham, et al.
Publicado: (2018)

Validation of DE50-MD dogs as a model for the brain phenotype of Duchenne muscular dystrophy
por: Crawford, Abbe H., et al.
Publicado: (2022)

Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E.C., et al.
Publicado: (2021)

Musculoskeletal magnetic resonance imaging in the DE50-MD dog model of Duchenne muscular dystrophy
por: Hornby, Natasha L., et al.
Publicado: (2021)

The skeletal muscle phenotype of the DE50-MD dog model of Duchenne muscular dystrophy
por: Hildyard, John C.W., et al.
Publicado: (2022)

Characterization of pulmonary function in Duchenne Muscular Dystrophy
por: Mayer, O.H., et al.
Publicado: (2015)

The force-temperature relationship in healthy and dystrophic mouse diaphragm; implications for translational study design
por: Murray, Jason D., et al.
Publicado: (2012)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l8ganm9es1jscn31lb0q6ll06d